A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis (Rinomax)
A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)
Sponsor: Fredrik Piehl
This PHASE3 trial investigates Generalized Myasthenia Gravis and is currently completed. Fredrik Piehl leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE3
Status: Unknown → Completed
-
Sep 2024 — Nov 2024 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Apr 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2019 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fredrik Piehl
For direct contact, visit the study record on ClinicalTrials.gov .